Erythropoietin Receptor Expression in Tumors
Author Information
Author(s): Sinclair A M, Rogers N, Busse L, Archibeque I, Brown W, Kassner P D, Watson J E V, Arnold G E, Nguyen K C Q, Powers S, Elliott S
Primary Institution: Amgen Inc.
Hypothesis
Is erythropoietin receptor (EpoR) overexpressed in human tumors?
Conclusion
The study found no evidence that EpoR is overexpressed in tumors or that it reaches the surface of tumor cells.
Supporting Evidence
- Amplification of the EPOR locus was rare in 1083 solid tumors.
- EPOR transcript levels in tumors were equivalent to or lower than levels in normal tissues.
- No EpoR protein was detected on the cell surface of tumor cell lines.
Takeaway
The study looked at cancer cells to see if they had more of a protein called EpoR, but they found that they didn't have much at all.
Methodology
The study analyzed genomic amplification and transcript levels of EpoR in 1083 solid tumors and various tumor cell lines using quantitative PCR and microarray analysis.
Potential Biases
Potential bias due to the use of non-specific antibodies for EpoR detection.
Limitations
The study's findings may be limited by the specificity of antibodies used to detect EpoR.
Participant Demographics
The study included a diverse range of 1083 solid tumor samples from various types of cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website